Bladder Cancer Initiating Cells (BCICs) Are Among EMA⁻CD44v6⁺ Subset: Novel Methods for Isolating Undetermined Cancer Stem (Initiating) Cells

REFERENCES

• Reya T., Morrison S. J., Clarke M. F., Weissman I. L. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105–111
   PubMed Web of Science ®Google Scholar
• Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645–648
   PubMed Web of Science ®Google Scholar
• Al-Hajj M., Wicha M. S., Benito-Hernandez A., Morrison S. J., Clarke M. F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983–3988
   PubMed Web of Science ®Google Scholar
• Singh S. K., Clarke I. D., Terasaki M., Bonn V. E., Hawkins C., et al. Identification of a Cancer Stem Cell in Human Brain Tumors. Cancer Research 2003; 63: 5821–5828
   PubMed Web of Science ®Google Scholar
• Singh S. K., Hawkins C., Clarke I. D., Squire J. A., Bayani J., et al. Identification of human brain tumour initiating cells. Nature 2004; 432(7015)396–401
   PubMed Web of Science ®Google Scholar
• Taylor M. D., Poppleton H., Fuller C., Su X., Liu Y., et al. Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 2005; 8(4)323–335
   PubMed Web of Science ®Google Scholar
• Fang D., Nguyen T. K., Leishear K., Finko R., Kulp A. N., et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005; 65(20)9328–9337
   PubMed Web of Science ®Google Scholar
• Kim C. F., Jackson E. L., Woolfenden A. E., Lawrence S., Babar I., et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005; 121(6)823–835
   PubMed Web of Science ®Google Scholar
• Gibbs C. P., Kukekov V. G., Reith J. D., Tchigrinova O., Suslov O. N., et al. Steindler Stem-Like Cells in Bone Sarcomas, Implications for Tumorigenesis. Neoplasia 2005; 7(11)967–976
   PubMed Web of Science ®Google Scholar
• Collins A. T., Berry P. A., Hyde C., Stower M. J., Maitland N. J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65(23)10946–10951
   PubMed Web of Science ®Google Scholar
• O'Brien C. A., Pollett A., Gallinger S., Dick J. E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445(7123)106–110
   PubMed Web of Science ®Google Scholar
• Ricci-Vitiani L., Lombardi D. G., Pilozzi E., Biffoni M., Todaro M., et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445(7123)111–115
   PubMed Web of Science ®Google Scholar
• Wang H. T., Chang J. W. Molecular pathology of low malignant bladder transitional cell carcinoma, a current perspective. Histol Histopathol 2005; 20(1)147–153
   PubMed Web of Science ®Google Scholar
• Quan H., Yong X., Wenlu L., Xiaoge Z., Wenxin L. Laser Capture Microdissection Combined with RNA in vitro Linear Amplification Detecting the Relevant Genes of Bladder Cancer. Chinese-German J of Clin Oncol 2005; 4(5)309–313
   Google Scholar
• Udomsakdi C., Lansdorp P. M., Hogge D. E., Reid D. S., Eaves A. C. Characterization of primitive hematopoietic cells in normal human peripheral blood. Blood 1992; 80(10)2513–2521
   PubMed Web of Science ®Google Scholar
• Goodell M. A., Brose K., Paradis G., Conner A. S., Mulligan R. C. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996; 183(4)1797–1806
   PubMed Web of Science ®Google Scholar
• Jacques Irani A, Nicolas Mottet B, Marıa, Jose Ribal Caparros C, Pierre Teillac D. New Trends in Bladder Cancer Management. European Urology Supplements 2007; 6: 388–395
   Web of Science ®Google Scholar
• Leemhuis T., Yoder M. C., Grigsby S., Agüero B., Eder P., et al. Isolation of primitive human bone marrow hematopoietic progenitor cells using Hoechst 33342 and Rhodamine 123. Exp Hematol 1996; 24(10)1215–1224
   PubMed Web of Science ®Google Scholar
• Spangrude G. J., Johnson G. R. Resting and activated subsets of mouse multipotent hematopoietic stem cells. Proc Natl Acad Sci USA 1990; 87(19)7433–7437
   PubMed Web of Science ®Google Scholar
• Lo K. C., Brugh V. M., Parker M., Lamb D. J. Isolation and enrichment of murine spermatogonial stem cells using rhodamine 123 mitochondrial dye. Biol Reprod 2005; 72(3)767–771
   PubMed Web of Science ®Google Scholar
• Niemeyer G. P., Hudson J., Bridgman R., Spano J., Nash R. A., et al. Isolation and characterization of canine hematopoietic progenitor cells. Exp Hematol 2001; 29(6)686–693
   PubMed Web of Science ®Google Scholar
• Spink K. E., Polakis P., Weis W. I. Structural basis of the Axin-adenomatous polyposis coli interaction. EMBO J 2000; 19(10)2270–2279
   PubMed Web of Science ®Google Scholar
• Taipale J., Beachy P. A. The Hedgehog and Wnt signalling pathways in cancer. Nature 2001; 411(6835)349–354
   PubMed Web of Science ®Google Scholar
• Pongracz J. E., Stockley R. A. Wnt signalling in lung development and diseases. Respir Res 2006; 26: 7, 15
   Google Scholar
• Bhardwaj G., Murdoch B., Wu D., Baker D. P., Williams K. P., et al. Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation. Nat Immunol 2001; 2(2)172–180
   PubMed Web of Science ®Google Scholar
• Lessard J., Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 2003; 423(6937)255–260
   PubMed Web of Science ®Google Scholar
• Kim J. H., Yoon S. Y., Kim C. N., Joo J. H., Moon S. K., et al. The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett 2004; 203(2)217–224
   PubMed Web of Science ®Google Scholar
• van Leenders G. J., Dukers D., Hessels D., van den Kieboom S. W., Hulsbergen C. A., et al. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol 2007; 52(2)455–463
   PubMed Web of Science ®Google Scholar
• Kim J. H., Yoon S. Y., Jeong S. H., Kim S. Y., Moon S. K., et al. Overexpression of Bmi-1 oncoprotein correlates with axillary lymph node metastases in invasive ductal breast cancer. Breast 2004; 13(5)383–388
   PubMed Web of Science ®Google Scholar
• Vonlanthen S., Heighway J., Altermatt H. J., Gugger M., Kappeler A., et al. The bmi-1 oncoprotein is differentially expressed in nonsmall cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer 2001; 84(10)1372–1376
   PubMed Web of Science ®Google Scholar
• Bapat S. A. Evolution of cancer stem cells. Semin Cancer Biol 2007; 17(3)204–213
   PubMed Web of Science ®Google Scholar
• Su I. H., Basavaraj A., Krutchinsky A. N., Hobert O., Ullrich A., et al. Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat Immunol 2003; 4(2)124–131
   PubMed Web of Science ®Google Scholar
• Berezovska O. P., Glinskii A. B., Yang Z., Li X. M., Hoffman R. M., et al. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle 2006; 5(16)1886–1901
   PubMed Web of Science ®Google Scholar
• Atlasi Y., Mowla S. J., Ziaee S. A., Bahrami A. R. OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer. Int J Cancer 2007; 120(7)1598–1602
   PubMed Web of Science ®Google Scholar
• Blanpain C., Horsley V., Fuchs E. Epithelial stem cells, turning over new leaves. Cell 2007; 128(3)445–458
   PubMed Web of Science ®Google Scholar
• Morrison S. J., Wright D. E., Cheshier S. H., Weissman I. L. Hematopoietic stem cells, challenges to expectations. Curr Opin Immunol 1997; 9(2)216–221
   PubMed Web of Science ®Google Scholar
• Potten C. S. Cell replacement in epidermis (keratopoiesis) via discrete units of proliferation. Int Rev Cytol 1981; 69: 271–318
   PubMedGoogle Scholar
• Tudor D., Locke M., Owen-Jones E., Mackenzie I. C. Intrinsic patterns of behavior of epithelial stem cells. J Investig Dermatol Symp Proc 2004; 9(3)208–214
   PubMed Web of Science ®Google Scholar
• Yin H., He Q., Li T., Leong A. S. Cytokeratin 20 and Ki-67 to distinguish carcinoma in situ from flat non-neoplastic urothelium. Appl Immunohistochem Mol Morphol 2006; 14(3)260–265
   PubMedGoogle Scholar
• Lin Z., Kim H., Park H., Kim Y., Cheon J., et al. The expression of bcl-2 and bcl-6 protein in normal and malignant transitional epithelium. Urol Res 2003; 31(4)272–275
   PubMed Web of Science ®Google Scholar
• Knudson A. G., Jr., Strong L. C., Anderson D. E. Heredity and cancer in man. Prog Med Genet 1973; 9: 113–158
   PubMedGoogle Scholar
• Rakha E. A., Boyce R. W., Abd El-Rehim D., Kurien T., Green A. R., et al. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol 2005; 18(10)1295–1304
   PubMed Web of Science ®Google Scholar
• Hollingsworth M. A., Swanson B. J. Mucins in cancer, protection and control of the cell surface. Nat Rev Cancer 2004; 4(1)45–60
   PubMed Web of Science ®Google Scholar
• Takashi M., Murase T., Kinjo T., Mitsuya H., Nagura H. Epithelial membrane antigen as an immunohistochemical marker for transitional cell carcinoma of the urinary bladder. Urol Int 1987; 42(3)170–175
   PubMed Web of Science ®Google Scholar
• Takashi M., Murase T., Mitsuya H., Koshikawa T., Nagura H., et al. Immunohistochemical localization of epithelial membrane antigen, carcinoembryonic antigen and secretory component in urinary bladder cancer. Hinyokika Kiyo 1986; 32(4)541–552
   PubMedGoogle Scholar
• Asamoto M., Fukushima S., Oosumi H., Tatemoto Y., Mori M. Immunohistochemical distribution of epithelial membrane antigen in bladder carcinomas as detected with a monoclonal antibody. Urol Res 1989; 17(5)273–277
   PubMed Web of Science ®Google Scholar
• Rudzki Z., Jothy S. CD44 and the adhesion of neoplastic cells. Mol Pathol 1997; 50(2)57–71
   PubMedGoogle Scholar
• Smith C. W., Patton J. G., Nadal-Ginard B. Alternative splicing in the control of gene expression. Annu Rev Genet 1989; 23: 527–577
   PubMed Web of Science ®Google Scholar
• Kaufmann M., Heider K. H., Sinn H. P., von Minckwitz G., Ponta H., et al. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 1995; 345(8950)615–619
   PubMed Web of Science ®Google Scholar
• Heider K. H., Dämmrich J., Skroch-Angel P., Müller-Hermelink H. K., Vollmers H. P., et al. Differential expression of CD44 splice variants in intestinal and diffuse type human gastric carcinomas and normal gastric mucosa. Cancer Res 1993; 53(18)4197–4203
   PubMed Web of Science ®Google Scholar
• Mulder J. W., Kruyt P. M., Sewnath M., Oosting J., Seldenrijk C. A., et al. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet 1994; 344(8935)1470–1472
   PubMed Web of Science ®Google Scholar
• Joensuu H., Ristamäki R., Klemi P. J., Jalkanen S. Lymphocyte homing receptor (CD44) expression is associated with poor prognosis in gastrointestinal lymphoma. Br J Cancer 1993; 68(2)428–432
   PubMed Web of Science ®Google Scholar
• Tran T. A., Kallakury B. V., Sheehan C. E., Ross J. S. Expression of CD44 standard form and variant isoforms in non-small cell lung carcinoma. Human Pathol 1997; 28(7)809–814
   PubMed Web of Science ®Google Scholar
• Wielenga V. J., van der Neut R., Offerhaus G. J., Pals S. T. CD44 glycoproteins in colorectal cancer, expression, function, and prognostic value. Adv Cancer Res 2000; 77: 169–187
   PubMed Web of Science ®Google Scholar
• Reinthaller A., Kainz C., Kohlberger P., Tempfer C., Gitsch G., et al. CD44 splice variants as prognostic factors in invasive cervix carcinoma. Gynakol Gedurt Shifliche Rundsh 1995; 35(1)16–19
   PubMed Web of Science ®Google Scholar
• Speiser P., Wanner C., Tempfer C., Mittelböck M., Hanzal E., et al. CD44 is an independent prognostic factor in earlystage cervical cancer. Int J Cancer 1997; 74: 185–188
   PubMed Web of Science ®Google Scholar
• Herrlich P., Zöller M., Pals S. T., Ponta H. CD44 splice variants, metastases meet lymphocytes. Immunol Today 1993; 14: 395–399
   PubMedGoogle Scholar
• Gunthert U., Hofmann M., Rudy W., Reber S., Zoller M., et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65(1)13–24
   PubMed Web of Science ®Google Scholar
• Kuncova J., Kostrouch Z., Viale M., Revoltella R., Mandys V. Expression of CD44v6 correlates with cell proliferation and cellular atypia in urothelial carcinoma cell lines 5637 and HT1197. Folia Biol (Praha) 2005; 51(1)3–11
   PubMed Web of Science ®Google Scholar
• Zieger K., Dyrskjøt L., Wiuf C., Jensen J. L., Andersen C. L., et al. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. Clin Cancer Res 2005; 11(21)7709–7719
   PubMed Web of Science ®Google Scholar
• Diggle C. P., Cruickshank S., Olsburgh J. D., Pellegrin S., Smith B., et al. Identification of genes up-regulated in urothelial tumors, the 67-kd laminin receptor and tumor-associated trypsin inhibitor. Am J Pathol 2003; 163(2)493–504
   PubMed Web of Science ®Google Scholar
• Wild P. J., Herr A., Wissmann C., Stoehr R., Rosenthal A., et al. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clin Cancer Res 2005; 11(12)4415–4429
   PubMed Web of Science ®Google Scholar
• Esposito I., Penzel R., Chaib-Harrireche M., Barcena U., Bergmann F., et al. Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. J Pathol 2006; 208(5)673–685
   PubMed Web of Science ®Google Scholar
• Busund L. T., Richardsen E., Busund R., Ukkonen T., Bjørnsen T., et al. Significant expression of IGFBP2 in breast cancer compared with benign lesions. J Clin Pathol 2005; 58(4)361–366
   PubMed Web of Science ®Google Scholar